Significant progress in ICI development has instigated a paradigm shift in patients with lung cancer, especially those with locally advanced NSCLC without EGFR/ALK alterations, for whom ICIs have been approved as second-line therapy after numerous trials [9,110,111,112]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.